Overview

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

TG Therapeutics, Inc.

Collaborators:

Abramson Cancer Center of the University of Pennsylvania
Memorial Sloan Kettering Cancer Center

Treatments:

Pembrolizumab